Key Insights

Highlights

Success Rate

86% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 52/100

Termination Rate

6.9%

2 terminated out of 29 trials

Success Rate

85.7%

-0.8% vs benchmark

Late-Stage Pipeline

21%

6 trials in Phase 3/4

Results Transparency

33%

4 of 12 completed with results

Key Signals

4 with results86% success

Data Visualizations

Phase Distribution

12Total
Not Applicable (1)
P 1 (1)
P 2 (4)
P 3 (3)
P 4 (3)

Trial Status

Completed12
Unknown9
Recruiting4
Terminated2
Withdrawn1
Active Not Recruiting1

Trial Success Rate

85.7%

Benchmark: 86.5%

Based on 12 completed trials

Clinical Trials (29)

Showing 20 of 20 trials
NCT07238114Active Not Recruiting

Liver Cirrhosis Patients With Invasive Pulmonary Aspergillosis: in Depth Understanding Clinical Host Risk Factors

NCT07330986Completed

Influenza A-associated Pulmonary Aspergillosis in Patients Admitted to the Intensive Care Unit in China

NCT07313527RecruitingPrimary

PCR for Aspergillus Fumigatus in Blood and Bronchoalveolar Lavage Fluid for Monitoring Cases of Invasive Aspergillosis: What is Its Prognostic Value

NCT03748069Recruiting

Influenza Associated Aspergillosis In-depth Investigation

NCT06537726Recruiting

Breath Analysis for the Detection of Invasive Fungal Infections

NCT05897294UnknownPrimary

Voriconazole Inhalation Powder for the Treatment of Pulmonary Aspergillosis

NCT03059992Phase 3Completed

Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment

NCT06654076Completed

Assessing Diagnostic Methods for Invasive Fungal Disease in Lung Transplant Recipients

NCT03672292Phase 2TerminatedPrimary

Evaluate Safety and Efficacy of the Coadministration of Ibrexafungerp With Voriconazole in Patients With Invasive Pulmonary Aspergillosis

NCT01782131Phase 3Completed

A Study of the Safety and Efficacy of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis (MK-5592-069)

NCT05860387Recruiting

Early Diagnosis of Invasive Lung Aspergillosis

NCT05982912UnknownPrimary

VOC in Breath Samples for the Diagnosis of IPA

NCT04172610CompletedPrimary

Prevalence of Influenza RelAted Invasive Aspergillosis

NCT04267497Phase 1CompletedPrimary

Nebulised Liposomal Amphotericin for Invasive Pulmonary Aspergillosis (NAIFI01 Study)

NCT05138666Not ApplicableUnknownPrimary

Non-invasive Tools to Diagnose Invasive Aspergillosis Infections in ICU Patients With COVID-19 and Other Conditions.

NCT05569824UnknownPrimary

LFD of Aspergillus Antigen in Paediatrics

NCT02058316CompletedPrimary

Bronchoalveolar Lavage Lateral-Flow Device Test for Invasive Pulmonary Aspergillosis: a Multicenter Study

NCT04848831UnknownPrimary

Diagnosis of Invasive Pulmonary Aspergillosis, Specific Testing in Bronchial Secretions Versus Bronchoalveolar Fluid

NCT04077697CompletedPrimary

Clinical and Prognostic Comparisons Between Invasive Pulmonary Aspergillosis With or Without Invasive Tracheobronchitis During Severe Influenza: a Retrospective Multicenter Cohort Study.

NCT03327727Phase 2Terminated

VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis (IA) in Adults

Scroll to load more

Research Network

Activity Timeline